HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
暂无分享,去创建一个
William Pao | Elisa de Stanchina | Marc Ladanyi | Maria E Arcila | Mark G Kris | Vincent A Miller | Xiaoling Song | Valentina Pirazzoli | Katerina Politi | Ken Takezawa | Yelena Y Janjigian | Caroline A Nebhan | Paula J Spitzler | Mary Ann Melnick | Kadoaki Ohashi | Greg J Riely
[1] M. Ladanyi,et al. Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay , 2011, Clinical Cancer Research.
[2] P. Jänne,et al. Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab , 2011, Science Translational Medicine.
[3] H. Groen,et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. Citri,et al. Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling , 2007, Oncogene.
[5] C. Mermel,et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[6] N. Hanna,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2008 .
[7] M. Ladanyi,et al. EGFR mutations in small-cell lung cancers in patients who have never smoked. , 2006, The New England journal of medicine.
[8] L. Tanoue,et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma , 2010 .
[9] Derek Y. Chiang,et al. The landscape of somatic copy-number alteration across human cancers , 2010, Nature.
[10] P. Jänne,et al. Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer , 2011, Clinical Cancer Research.
[11] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[12] Chris Sander,et al. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors , 2009, Oncogene.
[13] M. Ladanyi,et al. New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer , 2011, Clinical Cancer Research.
[14] Carlos L Arteaga,et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. , 2006, Cancer cell.
[15] H. Varmus,et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.
[16] N. Hanna,et al. EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib , 2006 .
[17] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[18] F. Hirsch,et al. EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR and KRAS Mutations in a Japanese Cohort , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[19] Trevor J Pugh,et al. Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients , 2007, BMC Cancer.
[20] W. Pao,et al. Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas , 2007, PLoS medicine.
[21] H. Varmus,et al. Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma , 2010, Disease Models & Mechanisms.
[22] Elisa Rossi,et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] N. Socci,et al. Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling , 2011, Science Translational Medicine.
[24] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[25] William Pao,et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.
[26] M. Meyerson,et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models , 2008, Oncogene.
[27] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[28] P. Jänne,et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Davide Corà,et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.
[30] J. Verweij,et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours , 2007, British Journal of Cancer.
[31] William Pao,et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. , 2009, The Journal of clinical investigation.
[32] M. Kris,et al. Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib , 2011, Clinical Cancer Research.
[33] S. Digumarthy,et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.
[34] L. Tanoue. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR , 2011 .
[35] Robert A. Beckman,et al. Antibody-Based Therapy for Solid Tumors , 2008, Cancer journal.
[36] Yan Sun,et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. , 2012, The Lancet. Oncology.
[37] P. Jänne,et al. OP 85 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab , 2011 .